Vertex Gears Up For Next Generation In CF Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Orkambi posts sales of $131m in its first quarter on the market, reaching 35% of CF patients eligible for therapy under its label. Firm also updated investors on plans for next-generation CF drugs
You may also be interested in...
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.